Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

High risk of bleeding following CAR T-cell therapy: Insights from the dutch “Follow that CAR!” registry

Amica Ko, Pim Mutsaers, Lukas Van Kleij, Frank Leebeek, Amaria Vledder, Elise Pennings, Anne Spanjaart, Janneke De Boer, Astrid Demandt, Jaap Van Doesum, Suzanne Van Dorp, Margot Jak, Maria Kuipers, Tom Van Meerten, Marjolein Van Der Poel, Joost Vermaat, Marie José Kersten, Mandy Lauw

Blood (2025) 146 (Supplement 1): 315.

https://doi.org/10.1182/blood-2025-315

Published: 2025

Journal Articles

End-of-study analysis of the HOPE-B trial confirms the durable efficacy and safety of etranacogene dezaparvovec hemophilia b gene therapy over 5 years

Steven Pipe, Wolfgang Miesbach, Michael Recht, Frank Leebeek, Nigel Key, Giancarlo Castaman, Susan Lattimore, Michiel Coppens, Sandra LeQuellec, Sean Gill, Vaibhav Mahajan, Douglass Drelich, Paul Monahan

Blood (2025) 146 (Supplement 1): 538.

https://doi.org/10.1182/blood-2025-538

Published: 2025

Journal Articles

Recombinant von willebrand factor for perioperative management of bleeding in pediatric patients with severe von willebrand disease: Interim results from a phase 3 multicenter study and a phase 3b continuation study

Shayla Bergmann, Bulent Zulfikar, Jessica Meznarich, Eric Mullins, Michael Wang, Shelley Crary, Frank Leebeek, Ali Mokdad, Yi Wang, Josh Weng, Jingmei Zhang

Blood (2025) 146 (Supplement 1): 1304.

https://doi.org/10.1182/blood-2025-1304

Published: 2025

Journal Articles

Clingen Coagulation Factor Deficiency Variant Curation Expert Panel: Meeting the Need for Recommendations to Curate Variants in the Coagulation Factor Genes

Shruthi Mohan, PhD, Kristy Lee, MS, CGC, Manuel Carcao, Bhavya S Doshi, MD, Kate Downes, PhD, Geoff Kemball-Cook, PhD, Frank Leebeek, MD PhD, Jamie McCreery, MS, CGC, Connie H. Miller, PhD, Amanda B Payne, MPH,PhD, Valerie Trapp-Stamborski, PhD, Barbara A. Konkle, MD, Keith Gomez, MBBS, PhD MRCP, FRCPath

Blood (2019) 134 (Supplement_1): 5794.

https://doi.org/10.1182/blood-2019-124842

Published: 2019

Journal Articles

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

Steven Pipe, MD, Adam Giermasz, MD PhD, Giancarlo Castaman, MD, Nigel S. Key, MBChB, FRCP, Susan U Lattimore, Frank Leebeek, MD PhD, Wolfgang Miesbach, MD PhD, Michael Recht, MD PhD, Esteban Gomez, MD, Alison Long, Robert Gut, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 3348.

https://doi.org/10.1182/blood-2019-128765

Published: 2019

Journal Articles

Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy

Frank Leebeek, K Meijer, MD, Michiel Coppens, MD, Peter Kampmann, MD, Robert Klamroth, Roger Schutgens, MD PhD MSc, Giancarlo Castaman, Erhard Seifried, MD, J Schwaeble, MD, Halvard Bonig, MD, Eileen K Sawyer, PhD, W Miesbach

Blood (2018) 132 (Supplement 1): 3476.

https://doi.org/10.1182/blood-2018-99-109995

Published: 2018

Journal Articles

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Blood (2018) 132 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2018-99-112447

Published: 2018

Journal Articles

Low ADAMTS13 Activity Is a Strong Risk Factor for Ischemic Stroke: A Prospective Cohort Study - the Rotterdam Study

Michelle Alida Helena Sonneveld, MD, Moniek de Maat, PhD, Marileen L.P. Portegies, MD, Albert Hofman, MD PhD, Peter L Turecek, PhD, Hanspeter Rottensteiner, PhD, Friedrich Scheiflinger, PhD, Peter J. Koudstaal, MD PhD, Mohammed A. Ikram, MD PhD, Frank Leebeek, MD PhD

Blood (2014) 124 (21): 113.

https://doi.org/10.1182/blood.V124.21.113.113

Published: 2014

Journal Articles

Fibrinogen γ' In the Budd-Chiari Syndrome: Results From a Multicenter Case-Control Study

Jasper Smalberg, PhD, Edith Koehler, PhD, Sarwa Darwish Murad, PhD, Aurelie Plessier, PhD, Juan-Carlos Garcia-Pagan, PhD, Susana Seijó, PhD, Philippe Langlet, PhD, Jonel Trebicka, PhD, Massimo Primignani, PhD, Moniek De Maat, PhD, Dick Rijken, PhD, Dominique Valla, PhD, Harry Janssen, PhD, Frank Leebeek

Blood (2010) 116 (21): 4213.

https://doi.org/10.1182/blood.V116.21.4213.4213

Published: 2010

Journal Articles

JAK2 Germline Genetic Variation In Budd-Chiari Syndrome and Portal Vein Thrombosis

Jasper Smalberg, PhD, Edith Koehler, PhD, Sarwa Darwish Murad, PhD, Aurelie Plessier, PhD, Juan-Carlos Garcia-Pagan, PhD, Susana Seijó, PhD, Philippe Langlet, PhD, Jonel Trebicka, PhD, Massimo Primignani, PhD, Moniek De Maat, PhD, Dominique Valla, PhD, Harry Janssen, PhD, Frank Leebeek

Blood (2010) 116 (21): 4212.

https://doi.org/10.1182/blood.V116.21.4212.4212

Published: 2010

Journal Articles

Circulating Endothelial Cells: A Potential Parameter of Organ Damage in Sickle Cell Anemia?

Michiel Strijbos, MD, Precious Landburg, MD, Erfan Nur, MD, Bart J. Biemond, MD, PhD, Frank Leebeek, MD, PhD, Jan-Willem Gratama, PhD, Ashley Duits, PhD, John-John Schnog, MD, PhD

Blood (2008) 112 (11): 4798.

https://doi.org/10.1182/blood.V112.11.4798.4798

Published: 2008

Journal Articles

Microparticle-Associated Tissue Factor Activity and Venous Thrombosis in Multiple Myeloma.

Frank Leebeek, MD, PhD, Yuana Yuana, Suzanne Osanto, Moniek de Maat, Hajo Auwerda, Rogier Bertina, Pieter Sonneveld, MD, PhD

Blood (2008) 112 (11): 1812.

https://doi.org/10.1182/blood.V112.11.1812.1812

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

High risk of bleeding following CAR T-cell therapy: Insights from the dutch “Follow that CAR!” registry

End-of-study analysis of the HOPE-B trial confirms the durable efficacy and safety of etranacogene dezaparvovec hemophilia b gene therapy over 5 years

Recombinant von willebrand factor for perioperative management of bleeding in pediatric patients with severe von willebrand disease: Interim results from a phase 3 multicenter study and a phase 3b continuation study

Clingen Coagulation Factor Deficiency Variant Curation Expert Panel: Meeting the Need for Recommendations to Curate Variants in the Coagulation Factor Genes

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Low ADAMTS13 Activity Is a Strong Risk Factor for Ischemic Stroke: A Prospective Cohort Study - the Rotterdam Study

Fibrinogen γ' In the Budd-Chiari Syndrome: Results From a Multicenter Case-Control Study

JAK2 Germline Genetic Variation In Budd-Chiari Syndrome and Portal Vein Thrombosis

Circulating Endothelial Cells: A Potential Parameter of Organ Damage in Sickle Cell Anemia?

Microparticle-Associated Tissue Factor Activity and Venous Thrombosis in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only